Home > Browse Research > Life Sciences > Pharmaceuticals > Drug Discovery

Drug Discovery: market research reports

Drug Discovery market research reports and industry analysis

TSLP Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... cells upon pathogen stimulation. TSLP can also activate dendritic cells, CD4+ T cells and CD8+ T cells. TSLP not only activate the JAK/STAT pathway but also induce phosphorylation of other signaling molecules including PI3K/Akt, ERK1/2 ... \| read more...	$5,621.25
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... signal transducer in both physiologic and pathologic angiogenesis. The binding of VEGF to VEGFR-2 leads to a cascade of different signaling pathways, resulting in the up-regulation of genes involved in mediating the proliferation and migration ... \| read more...	$5,621.25
Viral Carcinogenesis Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic virus (HTLV-1) and Kaposi's associated sarcoma virus (KSHV) contribute to 10-15% of the cancers worldwide. Via expression of many potent oncoproteins, these tumor ... \| read more...	$5,621.25
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... are today 103 companies plus partners developing 109 Wnt pathway targeting drugs in 385 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last ... \| read more...	$3,746.25
Analytical Tool - Leukemia 4/22/2013 \| published by: BioSeeker Group AB ... the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their ... \| read more...	$11,625.00
Analytical Tool - Peptides in Oncology 4/22/2013 \| published by: BioSeeker Group AB ... same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of ... \| read more...	$11,625.00
Apoptosis in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... cancer cells. There are today 282 companies plus partners developing 277 apoptotic drugs in 1179 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased drugs over the ... \| read more...	$5,621.25
Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... of the alpha chain of Fc epsilon RI. The activation pathways are regulated both positively and negatively by the interactions of numerous signaling molecules. These mediators and cytokines contribute to inflammatory responses. There are today ... \| read more...	$5,621.25
Gap Junctions in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication ... \| read more...	$5,621.25
GnRH Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... and FSH. There are today 137 companies plus partners developing 152 GnRH signaling pathway targeting drugs in 526 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount ... \| read more...	$5,621.25
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... today 55 companies plus partners developing 47 Hedgehog pathway targeting drugs in 225 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years ... \| read more...	$1,871.25
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 79 companies plus partners developing 71 IL-1 pathway targeting drugs in 282 developmental projects in cancer. In ... \| read more...	$3,746.25
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 514 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 48 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ... \| read more...	$5,621.25
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 19 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ... \| read more...	$1,871.25
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 20 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ... \| read more...	$3,746.25
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... with several human malignancies include leukemias, gastrointestinal stromal tumors and mastocytomas. There are today 160 companies plus partners developing 248 Kit receptor pathway targeting drugs in 970 developmental projects in cancer. In addition, there are ... \| read more...	$5,621.25
Liver Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... drugs over the last years amount to another 49 drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 154 ... \| read more...	$3,746.25
Lymphoma Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 85 drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you ... \| read more...	$5,621.25
Melanoma Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... R&D, five-year survival of advanced patients remains below 20%. There are today 251 companies plus partners developing 296 drugs targeting melanoma in development. In addition, there are 3 suspended drugs and the accumulated number of ... \| read more...	$5,621.25
Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 107 drugs. Modulators Of The Actin Cytoskeleton For The Treatment Of Cancer Drug Pipeline ... \| read more...	$5,621.25
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... are today 221 companies plus partners developing 256 nucleic acid therapy drugs in 567 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last ... \| read more...	$5,621.25
p53 Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and ... \| read more...	$3,746.25
Pancreatic Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... drugs over the last years amount to another 101 drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 235 ... \| read more...	$5,621.25
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, ... \| read more...	$5,621.25
Proteins in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 583 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 168 drugs. Proteins In Oncology Drug Pipeline Update lists ... \| read more...	$5,621.25

< prev 1 2 3 4 5 6 7 8 9 10 next >